Semax and Selank both trace back to a Soviet and, later, Russian research programme on regulatory peptides based at the Institute of Molecular Genetics, with the physiologist Ivan Petrovich Ashmarin and the chemist Nikolai Myasoedov associated with the work that produced both compounds during the 1980s. Understanding that shared origin explains why the two peptides share a stabilising tail and a research tradition despite being studied for different reported mechanisms. Background on Semax specifically is covered on the Semax research pillar page.
What is the regulatory peptide research tradition this programme belongs to?
Ivan Ashmarin, who headed the Department of Human and Animal Physiology at Moscow State University, worked for decades on what Russian-language literature describes as the neurotropic activity of regulatory peptides — short peptide fragments derived from larger hormones or precursor proteins that were reported to influence central-nervous-system function independently of the classical hormonal activity of their parent molecule. Under that research direction, two lines of work were pursued in parallel: the elaboration and study of ACTH(4-10) fragment analogues, which produced Semax, and the study of tuftsin fragment analogues, which produced Selank.
How did Semax emerge from this programme?
Semax was developed in the early 1980s by combining the ACTH(4-7) core — the shortest segment reported to retain behavioural activity from the ACTH(4-10) fragment — with a Pro-Gly-Pro stabilising tail intended to slow the enzymatic degradation that limited the native fragment's usefulness as a research tool. A study of N-terminal degradation of ACTH(4-10) and Semax by rat blood enzymes later confirmed the practical basis for that design choice, reporting that Semax was more resistant to the enzymes tested than the unmodified fragment. The broader family of ACTH(4-10)-derived research compounds this work sits within is covered in ACTH(4-10) fragment peptides.
How did Selank emerge as a parallel compound?
Selank was developed within the same programme using the identical PGP stabilising strategy, but applied to a fragment of tuftsin, an immunomodulatory tetrapeptide cleaved from immunoglobulin G, rather than to an ACTH fragment. A study of intranasal Selank administration in rats reported that it altered BDNF mRNA and protein levels in the hippocampus within hours of dosing — a neurotrophin-related finding that parallels the BDNF/TrkB signature most associated with the Semax reference vial, even though Selank's most-studied reported target is allosteric modulation of the GABA-A receptor rather than the neurotrophin pathway. This structural parallel and mechanistic divergence between the two compounds is explored in depth in the Semax vs Selank guide.
What did the earliest published research on these compounds report?
Foundational work on Semax reported increased BDNF protein and mRNA levels together with enhanced TrkB receptor phosphorylation in rat hippocampus following intranasal administration, establishing the neurotrophin-expression endpoint that dominates the later Semax literature. On the Selank side, a comparative clinical study of patients with generalised anxiety and neurasthenia reported anxiolytic effects considered comparable to a reference benzodiazepine, alongside antiasthenic and psychostimulant effects, marking an early point where the two compounds' research trajectories diverged toward different primary applications despite their shared origin.
How did the programme's output move from the Soviet period into modern Russian research?
The Institute of Molecular Genetics programme continued through the transition from Soviet to Russian scientific institutions, and both Semax and Selank went on to Russian pharmaceutical registration under specific indications within that country's own regulatory framework — a registration status that is specific to Russia and does not extend to the EU, a distinction covered in what Semax is. Later work in the same research tradition, including rodent studies combining Selank with reference anxiolytic compounds and further mechanistic work on both peptides, continued to be published through the 2000s and 2010s, extending a research lineage by then several decades old.
Why does this shared history matter for reading the literature today?
Recognising that Semax and Selank emerged from the same institutional programme, using the same stabilisation chemistry applied to two different parent hormones, helps explain patterns that otherwise look coincidental in the literature — why the two compounds are so often studied side by side, why some papers examine both together against a shared neurotrophin panel, and why their reference literature so often cites the same research group. A researcher building a review around either compound benefits from tracing citations back through this shared programme rather than treating each compound's literature as an isolated body of work, a synthesis attempted more broadly in the Semax research overview.
What other regulatory peptides came out of this research direction?
The Institute of Molecular Genetics programme associated with Ashmarin and Myasoedov extended beyond Semax and Selank to a broader set of regulatory peptide analogues studied across the Soviet and Russian periods, reflecting a research philosophy that short peptide fragments derived from larger precursor proteins could be engineered into stable, targeted research tools. Semax and Selank remain the two most extensively characterised and commercially available outputs of that programme, which is part of why they are so consistently discussed together in secondary literature and vendor documentation, including on this site.
How did the two compounds' clinical applications diverge over time?
Despite their shared stabilisation chemistry, Semax and Selank were studied and, in Russia, registered for different clinical contexts as their respective literatures matured — Semax more closely associated with post-stroke recovery and cognition-related research, Selank more closely associated with anxiety- and stress-related research. That divergence reflects the different core sequences each compound carries rather than any change in the underlying PGP-stabilisation strategy, and it is the reason the two are compared directly, rather than treated as interchangeable, in resources such as the Semax vs Selank guide.
What should a researcher take from tracing this shared history?
Recognising the common institutional origin behind Semax and Selank is useful less as historical trivia and more as a practical aid to literature review: search strategies that include the Institute of Molecular Genetics research group and its associated authors alongside compound-specific terms are more likely to surface the full relevant citation trail than a compound-name search alone, particularly for older Russian-language publications that are not always fully indexed under the compound name in English-language databases. This citation-tracking point is discussed further in the broader survey of the evidence base in Semax research overview.
How does this history compare with better-known Western peptide research programmes?
Unlike many Western peptide research efforts that developed within pharmaceutical company laboratories, the Semax and Selank programme developed primarily within Soviet and Russian academic institutions, which shaped both its publication pattern — concentrated in Russian-language neurology and physiology journals for much of its early history — and its translation into commercial research-reagent availability, which happened considerably later than the underlying science itself.
This research history is presented for research use only, as background for interpreting the primary literature rather than as a description of outcomes for any individual. Both compounds, along with the rest of the verified peptide range, are available in the catalogue with batch-specific COA documentation.
